Mylan Inc. announced that its subsidiary, Mylan Pharmaceuticals Private Ltd., has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome, a leading anti-fungal, is one of the first critical care products Mylan is offering. Critical care is a leading therapeutic category in India, with $2.6 billion in annual sales.

 

Mylan CEO Heather Bresch commented: “The introduction of Mylan’s Critical Care segment represents another milestone in the expansion of our commercial presence in India and supports our mission to expand access to high quality medicine around the world. Moreover, the Critical Care segment allows us to better satisfy the unmet medical needs of patients living with life-threatening diseases. The bacterial disease burden in India is among the highest in the world2 and as a result, critical care medicines play an increasingly important role in limiting morbidity and mortality.”

 

Bresch continued: “As an indicator of disease burden, pneumonia causes an estimated 410,000 deaths in India each year. Many of these deaths occur because patients do not have access to life-saving antibiotics. We look forward to playing a central role in expanding access to affordable, quality medicine that these individuals desperately need.”

 

Mylan President Rajiv Malik added, “This new segment further diversifies our product offerings in India. In the past 18 months alone, we have delivered on our commitment to providing high quality medicine to patients in India through the introduction of four unique and innovative segments– Antiretroviral, Women’s Care, Oncology and, now, Critical Care. We are pleased to offer AmBisome as one of our first critical care products, and we look forward to introducing several more high-growth critical care products, including high-end antibiotics, in the near future.”

 

AmBisome treats life-threatening, systemic fungal infections and the parasitic disease visceral leishmaniasis. The product is the innovator brand of Liposomal Amphotericin B and is widely accepted by hematologists, oncologists and intensivists for the treatment of suspected or definitive systemic fungal infections.

 

Date: March 11, 2014

Source: Mylan